Table 1.

Baseline characteristics of patients in the training cohort (n = 211) including variables with a possible impact on survival analysis

FactorN%
Median age, y (range) 59 (18-88)  
Age ≥60 y 104 49 
Sex, male 95 45 
B symptoms present 73 of 202 36 
Extranodal involvement 115 55 
ECOG PS >1 27 of 199 14 
LDH > ULN 72 of 175 41 
Albumin <35 g/L 58 of 175 33 
Hb >12g/dL 66 of 196 34 
Platelet count <150 × 109 cells/L 111 of 195 57 
ANC >6.5 × 103/ml 55 of 188 29 
Histotypes   
PTCL-NOS 129 of 211 61 
AITL 28 of 211 13 
ALCL ALK– 54 of 211 26 
Therapy 175 of 211 83 
Best supportive care 12 7 
CHT alone 127 of 163 78 
RT alone 5 of 163 3 
CHT/RT 24 of 163 15 
CHT and HDT/ASCT 7 of 1163 4 
CHT regimens 161 of 211 76 
Anthracycline 119 of 161 75 
Anthracycline/etoposide 24 of 161 15 
Etoposide 7 of 161 4 
Other 11 of 161 6 
Response to treatment 156 of 211 74 
CR 97 of 156 63 
PR 24 of 156 15 
PD 35 of 156 22 
FactorN%
Median age, y (range) 59 (18-88)  
Age ≥60 y 104 49 
Sex, male 95 45 
B symptoms present 73 of 202 36 
Extranodal involvement 115 55 
ECOG PS >1 27 of 199 14 
LDH > ULN 72 of 175 41 
Albumin <35 g/L 58 of 175 33 
Hb >12g/dL 66 of 196 34 
Platelet count <150 × 109 cells/L 111 of 195 57 
ANC >6.5 × 103/ml 55 of 188 29 
Histotypes   
PTCL-NOS 129 of 211 61 
AITL 28 of 211 13 
ALCL ALK– 54 of 211 26 
Therapy 175 of 211 83 
Best supportive care 12 7 
CHT alone 127 of 163 78 
RT alone 5 of 163 3 
CHT/RT 24 of 163 15 
CHT and HDT/ASCT 7 of 1163 4 
CHT regimens 161 of 211 76 
Anthracycline 119 of 161 75 
Anthracycline/etoposide 24 of 161 15 
Etoposide 7 of 161 4 
Other 11 of 161 6 
Response to treatment 156 of 211 74 
CR 97 of 156 63 
PR 24 of 156 15 
PD 35 of 156 22 

ANC, absolute neutrophil count; CHT, chemotherapy; CR, complete response; CRP, C-reactive protein; Hb, hemoglobin; PD, progressive disease; PR, partial response; ULN, upper limit of normal.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal